Anti CD47 Drugs Market is booming driven by promising oncology pipeline

The anti CD47 drugs market comprises cell-signaling regulatory protein CD47 that acts as a "don't eat me" signal to macrophages and suppresses the immune system's ability to clear cancer cells or foreign invaders from the body. Anti CD47 drugs block this protein and enable macrophages to phagocytose cancer cells. Several pharmaceutical companies are developing monoclonal antibodies targeting CD47 along with combination therapies for hematological as well as solid tumors.

The anti CD47 drugs market is estimated to be valued at USD 0.14 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 42.9% from 2024 to 2031.

Key Takeaways

Key players operating in the anti CD47 drugs market are AbbVie, Celgene, Forty Seven Inc, Trillium Therapeutics, Taiho Pharmaceutical among others. Fort-Seven Inc's magrolimab is the most advanced anti-CD47 agent in clinical development which has shown promising results in Phase 1 trials for myelodysplastic syndrome and acute myeloid leukemia.

The growing incidence of cancer worldwide along with high unmet need of effective treatments are fueling the demand for Anti CD47 Drugs Market. According to WHO, cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. Anti CD47 drugs are emerging as a promising strategy to combat cancer both as monotherapy and in combination with other immune checkpoint inhibitors or chemotherapy.

Leading players are exploring strategic collaborations and partnerships to expand their clinical pipeline and market presence globally. In 2021, Forty Seven was acquired by Gilead Sciences for $4.9 billion to accelerate the development of magrolimab. Other players are likely to follow the suit through mergers and acquisitions in the coming years to tap into new geographical territories and consolidate their market share.

Market key trends

One of the key trends gaining traction in the anti CD47 drugs market is their evaluation in combination with other immune checkpoint inhibitors. Preclinical studies have shown that dual blockade of CD47 and checkpoints like PD-1 or TIGIT produces synergistic antitumor effects. Ongoing clinical trials are exploring triple combinations of CD47 inhibitors with PD-1/PD-L1 and CTLA-4 antibodies for malignancies with high unmet need like pancreatic cancer. This combination strategy holds promise to induce robust immune activation against difficult-to-treat tumors.
Porter's Analysis

Threat of new entrants: High research and development costs pose a major entry barrier.

Bargaining power of buyers: Large pharmaceutical companies have significant influence over price setting.

Bargaining power of suppliers: Suppliers of raw materials have limited influence given alternative sources.

Threat of new substitutes: Targeted immunotherapies pose the main competition but have not replaced anti-CD47 drugs yet.

Competitive rivalry: Competition is intense as major pharmaceutical companies race to develop advanced anti-CD47 drugs.

Geographical Regions

North America currently holds the largest share of the anti-CD47 drugs market owing to supportive regulatory environment and presence of major pharmaceutical companies in US and Canada.

Asia Pacific is poised to grow at the fastest rate over the forecast period due to rising healthcare spending, large patient pool, and growing penetration of CD47 drug therapies across major Asian economies like China and India.

Get this Report in Japanese Language: 抗CD47薬市場

Get this Report in Korean Language: 항 CD47 약물 시장

Author Bio:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)